Naproxcinod Gets Joint Advisory Committee; Will It Lower NicOx's Blood Pressure?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's decision to include both Arthritis Drugs and Risk Management panels in May 12 review suggests focus will on cardiovascular risks of the osteoarthritis drug.
You may also be interested in...
NicOx Takes It In The Gut: FDA Not Accepting Naproxcinod Claims On Blood Pressure Or GI Safety
FDA reviewers recommend that claims about blood pressure and ulcer benefits not be included in product label, on eve of advisory committee meeting.
NicOx Takes It In The Gut: FDA Not Accepting Naproxcinod Claims On Blood Pressure Or GI Safety
FDA reviewers recommend that claims about blood pressure and ulcer benefits not be included in product label, on eve of advisory committee meeting.
NicOx finds new partner Bausch & Lomb for Phase II Glaucoma Candidate
Deal shows - once again - that all is not lost when Big Pharma hands back a product